Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stempeucel in CLI due to Buerger's Disease
NCT03056742Phase 2Withdrawn
- Sponsor
- Stempeutics Research
- Start
- Feb 2017
- Primary completion
- Apr 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Stempeucel in thromboangiitis obliterans (TAO), sponsored by Stempeutics Research. Primary endpoints: Relief of the rest pain at 6 months and Reduction of ulcer area in the target limb at 6 months. Planned start Feb 2017; status: withdrawn.
02
Drugs
Stempeucel
03
Conditions
thromboangiitis obliterans (TAO)
Beyond the preview
Go deeper on NCT03056742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056742.